Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Nektar Therapeutics Surged Today

By Cory Renauer - Updated Apr 15, 2019 at 5:31PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors liked what the company had to say about the year ahead.

What happened

Check out the latest Nektar Therapeutics earnings call transcript.

Shares of Nektar Therapeutics (NKTR 3.84%), a biopharmaceutical company, are on the move following its presentation at the J.P. Morgan Healthcare conference. The stock climbed 11.1% during Tuesday's session as investors cheered Nektar's 2019 to-do list.

So what

Nektar has commercial-stage drugs, but sales and royalty revenue from partners that market its treatments trickled in at just $41 million during the first nine months of 2019. Investors nervous about NKTR-214 and its ability to boost the efficacy of PD-1 checkpoint inhibitors have hammered the stock more than 60% lower since a peak last March.

Hand drawing an upward-sloping chart on a chalkboard

Image source: Getty Images.

Last year, Bristol-Myers Squibb (BMY 1.49%) paid Nektar $1.85 billion up front for rights to NKTR-214. Investors were encouraged to hear that the company finished 2018 with $1.92 billion in cash and investments, thanks largely to Bristol's contribution.

In 2019, Nektar has a lot of plans for that cash, including:

  • Potential approval and launch of NKTR-181, an abuse-deterrent opioid painkiller that doesn't induce an addictive state of euphoria.
  • Human proof-of-concept data from a potential new autoimmune drug, NKTR-358.
  • Two new phase 1b studies of NKTR-358 in autoimmune conditions, to be initiated by Eli Lilly.
  • A phase 1 study of NKTR-255 in multiple myeloma.

Now what

Although Nektar has lots of cash to develop new treatments, it looks like the company will shovel a lot of it toward NKTR-214 in 2019. The candidate combined with Opdivo has produced interesting tumor response rates among small groups of patients receiving both drugs, but there's a good chance that Opdivo is doing all the work.

Instead of waiting for controlled data to find out if NKTR-214's the real thing, the partners will expand the number of ongoing registrational studies from four to 18 by the end of June. The first study comparing NKTR-214 plus Opdivo to Opdivo on its own started in the third quarter. If the newly diagnosed melanoma patients given Nektar's drug don't show a clear benefit, the rest of the program will crash and burn.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Nektar Therapeutics Stock Quote
Nektar Therapeutics
NKTR
$5.14 (3.84%) $0.19
Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
BMY
$75.57 (1.49%) $1.11

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/15/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.